Prescribing overview
An intravenous equine bisphosphonate for clinical signs of navicular syndrome in horses aged four years and older.
A navicular-syndrome diagnosis and a broader hoof-care plan remain important. Treatment response is assessed over time, while renal and gastrointestinal reactions can occur around infusion. Plan hydration, medication transitions and post-treatment observation before administration.
Key prescribing checks
- Review the source-specific safety card and monitoring plan before use.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Horses
U.S. labeled/regulatory equine use; see exact scopeControl of clinical signs associated with navicular syndrome
Horses four years and older; intravenous infusion. Not a general treatment authorization for every lameness.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Bisphosphonates inhibit osteoclast-mediated bone resorption. FDA notes that the precise therapeutic mechanism in equine navicular syndrome remains unknown.
Absorption, distribution, metabolism and elimination
Tiludronate binds bone and persists beyond plasma exposure. Metabolism is minimal and urinary excretion predominates; renal impairment can increase toxicity risk.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Tildren
U.S. equine Tildren infusion; manufacturer insert and FDA safety guidance.
Contraindications · when not to use
- Known hypersensitivity to tiludronate or mannitol.
- Impaired renal function or a history of renal disease.
Precautions & monitoring
- Use caution with HYPP, hypocalcemia or conditions worsened by mineral shifts. Safety below four years is unestablished; avoid pregnant, lactating or breeding mares.
- Not for horses intended for human consumption.
This is a selected source summary, not exhaustive prescribing guidance.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Colic is a prominent infusion-related reaction. Kidney injury, mineral/electrolyte disturbances and hypersensitivity are important risks.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
A veterinarian must select and prepare the label-specific infusion. No numerical dose, infusion calculator or fixed NSAID washout is provided.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Tildren
U.S. equine Tildren infusion; manufacturer insert and FDA safety guidance.
- Do not use concurrently with NSAIDs; acute renal failure is a risk. No universally safe washout interval is established.
- Review other nephrotoxic drugs and drugs affecting calcium.
Monitoring
Assess hydration and renal function; observe closely through infusion and for four hours afterward. Follow renal values and relevant electrolytes.
Client counseling
Report colic, reduced appetite, fever or changes in drinking and urination. Consult the veterinarian before giving an NSAID afterward.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Use aseptic preparation and label-specific solution storage. Do not mix with calcium-containing fluids such as lactated Ringer solution.
Brands, formulations & ingredient identity
Active ingredients
Tiludronate disodium
Other searchable names: Tiludronic acid · Tildren
Tildren contains tiludronate disodium; clodronate products are different ingredients and are not interchangeable.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Tildren
- Formulation
- Sterile powder for intravenous infusion
- Label / product scope
- Horses
Requires reconstitution and further dilution.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
